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Abstract
Background: Routine, initial, empiric vancomycin dosing by clinicians in postoperative coronary artery
bypass grafting (CABG) patients was identified as a potential patient safety issue in the Cardiovascular
Intensive Care Unit (CVICU) because the rate of postoperative acute renal insufficiency (ARI) and average
patient Body Mass Index (BMI) > 35 kg/m2 were significantly higher in our institution than those of the
Society of Thoracic Surgeons (STS) database. A vancomycin dosing nomogram was derived from the local
patient population in the attempt to improve patient safety by convincing clinicians to use an evidence-
based approach to vancomycin prescription.
Methods: We analyzed two different treatment strategies that were applied consecutively to an intensive
care unit population. CABG patients dosed empirically with vancomycin (group 1, pre-nomogram) were
compared with CABG patients dosed using a vancomycin dosing nomogram (group 2, post-nomogram)
derived from the hospital population using an Internet program that facilitated creation of a local
nomogram. The two groups were analyzed as to age, sex, body mass index, creatinine clearance, and
vancomycin dosage using logistic regression and testing for continuous and categorical variables.
Results: Nomogram use decreased the number of patients receiving the customary dose of one gram
every 12 hours in those group 2 patients with diminished CrCl as compared with those in group 1 with
diminished CrCl (group 2, 2/21 vs. group 1, 14/21, p < .0001), as well as in those with a normal creatinine
clearance, (group 2, 2/15 vs. group 1, 26/34, p < .0001). Therefore, nomogram use affected the customary
dose of one g vancomycin every 12 hours between the two groups overall (group 1, 40/55 vs. group 2, 4/
36, p < .001), whereby 32/36 (88.9%) of group 2 patients had their dosing altered when compared to what
would have been formerly prescribed, p < .0001. Furthermore, nomogram use resulted in fewer doses of
antibiotics per year resulting in a cost savings to the hospital with no increase in the rates of infection.
Conclusion: Implementation of the nomogram resulted in a more appropriate antibiotic utilization,
regardless of creatinine clearance, that decreased costs without increasing infection rates.
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Introduction
Vancomycin is used in antibiotic prophylaxis in penicil-
lin-allergic patients and postoperatively to treat life-
threatening, multi-drug resistant gram positive infections.
Complications with vancomycin use include renal dys-
function [1], inappropriate dosing in obese patients [2]
and ototoxicity [3]. In view of these potential complica-
tions, the initial, routine, empiric dosing of one gram (g)
of vancomycin intravenously (IV) every 12 hours in post-
operative CABG patients was identified as a patient safety
issue at our institution for two reasons. A larger than
expected percentage of these patients had (1) increased
rates of postoperative ARI (increase in serum creatinine to
greater than 2.0 mg/dl, or ≥ 50% increase in creatinine
over baseline preoperative value) [4] and (2) a BMI > 35
kg/m2. Both exceeded the norms of the STS database [5].
We determined that there was a need for a standardized
approach to vancomycin dosing by physicians in order to
avoid complications.
The 2006 Disease-Specific Care National Patient Safety
Goals of the Joint Commission on Accreditation of Health
Care Organizations included the objective (goal #3) of
improving the safety of medication use [6]. In support of
this goal we report an intervention by a critical care team
representing pharmacy and anesthesiology that imple-
mented a mandatory, evidence-based program for vanco-
mycin administration in which a locally derived
nomogram was utilized for dosing, as opposed to empiric
administration by clinicians. The nomogram is unique
because it was derived from the hospital's database with
the intent to be specific and continuously adjustable using
ongoing data collection. Although generic vancomycin
dosing nomograms are available [7-9], we anticipated that
(1) the development of a locally derived nomogram
would help clinician acceptance of a unified approach to
antibiotic prescribing by eliminating the "not invented
here" syndrome where external experience is erroneously
discounted, and (2) mandatory implementation of this
nomogram would correct clinicians' empiric prescribing
habits by providing an evidence-based method for dosing
vancomycin that would result in more appropriate antibi-
otic prescription and utilization, thus enhancing patient
safety.
Methods
A locally developed vancomycin nomogram was imple-
mented as part of a performance improvement project in
the CVICU of an academically affiliated hospital. Institu-
tional Review Board approval was obtained. The CVICU
differed from the hospital's general medical-surgical
intensive care unit in that it had (1) a multidisciplinary
care team comprised of anesthesiology, surgery, nursing,
pharmacy, and respiratory therapy that rounded daily on
the patients, and (2) it had a dedicated data collection sys-
tem. Starting 1 December 2003 a consecutive sample of
patients who had CABG surgery and received empiric van-
comycin (group 1, n = 55) was compared with a consecu-
tive sample of CABG patients who received vancomycin
dosing by nomogram (group 2, n = 36). The nomogram
was derived using data from 75 consecutive prior CABG
patients who had received an initial vancomycin-loading
dose of 15–20 mg/kg, and five subsequent maintenance
doses of 10–15 mg/kg. The trough and peak levels were
analyzed to determine each patient's pharmacokinetic
profile, as required by the Internet support program, Glo-
balRPh, which was used to create the hospital nomogram
[10]. Thus, a nomogram was created by the pharmacy spe-
cifically for patients at our institution that differed from
previously published generic nomograms [7-9]. ARI was
defined in this study as a creatinine clearance (CrCl) < 60
milliliters/minute, according to the American Kidney
Foundation guidelines [11]. The serum creatinine level
was not used as a marker of ARI because the STS had been
considering a revision of the definition [4]. All vancomy-
cin doses were given IV.
Statistical analysis included use of t-testing with the
assumption of equal variances for continuous variables,
and Fisher exact test for categorical variables. A logistic
regression model was used to test for differences in CrCl
between groups 1 and 2 and for adjusting for the con-
founding effect of age and sex. All analyses were done
using SAS 9.1 (SAS Institute, Cary NC). P-values < 0.05
were considered statistically significant.
Results
The pre-nomogram (group 1) and post-nomogram
(group 2) groups were similar for age (65.7 vs. 64.2), male
sex (54.6% vs. 61.1%), and BMI (29.2 kg/m2 vs. 28.8 kg/
m2) (Table 1). However, when age and sex were compared
with creatinine clearance (regardless of group) there was a
difference in that those with a decreased creatinine clear-
ance were older (70.1 years vs. 60.8 years) and female
(52.4% vs. 34.7%). A logistic regression of these variables
was determined and returned a p value of 0.017 (Table 2).
In group 1, 40/55 (72.7%) patients received an initial
empiric dosing of one g of IV vancomycin every 12 hours
while the other 15 patients received doses ranging from
0.5 g IV every 12 hours to 1.25 g every 48 hours. Physi-
Table 1: Equivalence of parameters between groups
Pre-nomogram Post-nomogram p-value
Age (mean ± sd) 65.7 ± 12.3 64.2 ± 11.7 0.554
Gender % female 45.5 38.9 0.536
BMI (mean ± sd) 29.2 ± 5.4 28.8 ± 6.6 0.774
sd = standard deviation; P < .05 was considered statistically significantPatient Safety in Surgery 2007, 1:2 http://www.pssjournal.com/content/1/1/2
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cians dosed all 55 patients in a self-determined manner.
Using the nomogram, only 4/36 (11.1%) of group 2
patients received the customary vancomycin dose of one g
IV every 12 hours. Therefore, 32/36 (88.9%) of group 2
patients had their dosing altered when compared to what
would have been formerly prescribed, p < .0001.
The effect of the nomogram was also examined on subsets
of patients according to their CrCl. Group 2 had a higher
percentage of patients with a decreased CrCl, 21/36
(58.3%) vs. 21/55 (38.2%), p < .0001. In group 1 14/21
(66.7%) of patients with a decreased CrCl received an ini-
tial regimen of one g vancomycin IV every 12 hours com-
pared to 2/21 (9.5%) in group 2 patients with a decreased
CrCl, p < .0001. Additionally, even those with a normal
CrCl exhibited decreased dosing of one g vancomycin IV
every 12 hours post-nomogram, 26/34 (76.5%) vs. 2/15
(13.3%), p < .0001.
Figure 1 demonstrates that 40/44 (90.9%) patients who
received one g vancomycin IV every 12 hours were in the
pre-nomogram group, whereas prescription of this vanco-
mycin dosage decreased in post-nomogram group, 15/47
(31.9%), p < .0001. There was no significant difference in
the number of antibiotic trough levels performed, or in
the number of elevated troughs in the two groups, regard-
less of CrCl. All clinicians prescribing antibiotics in the
CVICU complied with use of the nomogram without
objection. Infection rates were not affected by the nomo-
gram when comparing years 2001–2003, collectively,
with year 2005 (Table 3). Based upon the favorable results
shown by a review of the data, use of the nomogram was
then instituted as part of routine practice in the CABG
population. This practice was then extended hospital-
wide and resulted in a reduction of the annual number of
doses by 1200.
Discussion
Cardiac surgery patients have perioperative risk factors
such as renal failure and obesity that may influence van-
comycin dosing and clearance [1,2]. The percentage of
CABG patients with increased levels of serum creatinine
and obesity was a concern because the patients' increased
postoperative serum creatinines, or ARI, exceeded that of
the STS database, 6.75% vs. 3.47% (p < .001), as did their
BMI > 35 kg/m2, 20.4% vs. 13.4% (p < .001) [5]. Ototox-
icity is a known complication of vancomycin therapy and
was not addressed by this study. However, since overall
dosage decreased for the hospital population, it could be
presumed that this risk decreased.
The routine prescription of one g of vancomycin IV every
12 hours, without initially taking into consideration the
patient's CrCl, was a prescribing habit that was corrected
through the creation of a locally derived nomogram. The
nomogram changed the dose that would have been for-
merly prescribed in 88.9% of group 2 patients. This was
evident in those with and without increased CrCl. In view
of the fact that those with decreased CrCl were older, and
that group 2 had a significantly increased percentage of
Table 3: Infection rates by site
2001–2003 (n = 504) 2005 (n = 219) p-value
Leg 14(2.78%) 2(0.91%) 0.117
Sternum 1(0.20%) 0(0.0%) 0.510
Urinary tract 9(1.79%) 4(1.82%) 0.969
Pneumonia 15(2.98%) 4(1.90%) 0.375
Septicemia 7(1.39%) 3(1.20%) 0.984
P < .05 was considered statistically significant
Table 2: Logistic regression variables
Estimate p-value OR 95% CI
Group 0.60 0.017 3.34 1.24–9.03
Gender -0.48 0.053 0.38 0.15–1.01
Age -0.08 0.0001 0.92 0.88–0.96
OR = odds ratio; Cl = confidence limits; P < .05 was considered 
statistically significant
Creatinine clearance (CrCl) vs. vancomycin dosage in group  1 (pre-nomogram) and group 2 (post-nomogram) by per- centage of patients receiving one gram intravenously every  12 hours, or a dosage other than one gram intravenously  every 12 hours Figure 1
Creatinine clearance (CrCl) vs. vancomycin dosage in group 
1 (pre-nomogram) and group 2 (post-nomogram) by per-
centage of patients receiving one gram intravenously every 
12 hours, or a dosage other than one gram intravenously 
every 12 hours.Patient Safety in Surgery 2007, 1:2 http://www.pssjournal.com/content/1/1/2
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patients with a decreased CrCl, it may be inferred that they
benefited from use of the nomogram.
There are generic vancomycin dosing nomograms that are
available and well-validated [7-9]. However, our nomo-
gram's creation and implementation tailored time inter-
vals and doses to our population's CrCl that differed from
the generic versions. This convinced physicians to elimi-
nate their empiric vancomycin dosing, thereby allowing
more appropriate antibiotic prescription and utilization.
Ready physician acceptance of this format occurred
because of the potential for increased safety, and because
pharmacy calculated the CrCl and antibiotic dose through
the locally derived nomogram which facilitated the clini-
cians' practice. The nomogram's application hospital-
wide resulted in excess of $80,000 in annual savings
(1200 vancomycin doses per annum at $70 per dose).
There is a growing body of evidence that an individual's
genetic background (pharmacogenetics) can influence
responses to medications (the metabolism of codeine is a
classic example) [12]. Additionally, a local population
also might differ enough from the national norm, by eth-
nicity for example, so that a locally derived nomogram
would be appropriate [13]. The fact that in Ohio 60.2% of
the population is overweight or obese lends further sup-
port to local nomogram use in antibiotic prescription
[14]. Therefore a locally derived nomogram tailoring
doses and dosing intervals to the the CrCl of a particular
population may be of value, not only as an evidenced-
based method of antibiotic prescription, but also as a
more effective means of treatment. What must be empha-
sized is that this nomogram intervention caused clinicians
to prescribe an antibiotic in a commensurate manner,
with pharmacy oversight, resulting in financial savings
that did not raise infection rates. The project was not
designed to answer the question of whether locally
derived nomograms are better than generic nomograms; it
was implemented as a performance improvement project.
It was a pre-emptive attempt to improve patient safety by
convincing clinicians to use an evidence-based approach
to vancomycin prescription. Additionally, our institu-
tion's ARI did decrease over time by nearly one half to
3.4% (2006) and now approaches the STS database norm.
The previously elevated rates of ARI could not be attrib-
uted soley to vancomycin, and neither can the current
improvement be entirely attributed to use of the nomo-
gram. The hospital staff have made a considerable effort to
effect a policy of appropriate hydration in patients, i.e.,
before and after cardiac catheterization and periopera-
tively. Therefore, this improvement of ARI must be con-
sidered to be multifactorial.
It must be noted that our study design had limitations. We
analyzed two different treatment strategies that were
applied consecutively to an intensive care unit popula-
tion. Therefore, it was not randomized, so allocation to
treatment groups was not possible. Some specific charac-
teristics other than age, sex, and BMI may have been dif-
ferent between the groups. For example, a history of
dysrhythmias, variations in ejection fraction, number and
types of vessels bypassed, the types of bypass conduits
used (veins vs. arteries), and the duration of cardiopulmo-
nary bypass could affect outcomes. Finally, other factors
beside the nomogram may be responsible for the out-
come reported, such as the decision of a physician to over-
ride the nomogram based on an unusual clinical situation
or presentation.
This intervention improved patient care by (1) decreasing
the total number of antibiotic doses (risk events) to which
the population was exposed, (2) providing a consistent
evidence-based method of vancomycin prescription that
clinicians incorporated into practice, and (3) promoting a
culture of safety. We hope presentation of this successful
implementation of an evidence-based method will
encourage our colleagues to use this approach as a basis
for improved antibiotic utilization and enhanced patient
safety in the prescription of medications.
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